类Polo激酶作为免疫调节剂：癌症免疫治疗的新前沿
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy.
作者信息
Jaiswal Tanya, Chhabra Gagan, Ahmad Nihal
机构信息
Department of Dermatology, University of Wisconsin, Madison, WI 53705, USA.
Department of Dermatology, University of Wisconsin, Madison, WI 53705, USA; William S. Middleton Memorial Veterans Hospital, Madison, WI, 53705, USA.
出版信息
Trends Cancer. 2025 Aug 29. doi: 10.1016/j.trecan.2025.08.003.
Abstract
Cancer immunotherapy has transformed treatment but faces challenges such as immune evasion and toxicity. Polo-like kinases (PLKs), frequently dysregulated in tumors, are emerging as key immune modulators. Combining PLK inhibition with immunotherapy may overcome resistance, enhance antitumor responses, and improve clinical outcomes, offering an optimally efficient strategy for cancer treatment.
摘要
癌症免疫疗法已经改变了治疗方式，但面临着免疫逃逸和毒性等挑战。在肿瘤中经常失调的波罗样激酶（PLK）正成为关键的免疫调节剂。将PLK抑制与免疫疗法相结合可能会克服耐药性，增强抗肿瘤反应，并改善临床结果，为癌症治疗提供一种最优效的策略。
相似文献
1
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy.
Trends Cancer. 2025 Aug 29. doi: 10.1016/j.trecan.2025.08.003.
2
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.
4
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
The Role of Immunotherapy and Immune Modulators in Hormone-Positive Breast Cancer: Implications for Localized and Metastatic Disease.
J Clin Med. 2025 Jun 17;14(12):4322. doi: 10.3390/jcm14124322.
6
Current studies of immunotherapy in head and neck cancer.
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
7
Polo-like kinases and UV-induced skin carcinogenesis: What we know and what's next.
Photochem Photobiol. 2025 Jul 9. doi: 10.1111/php.70002.
8
MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway.
Acta Biomater. 2025 Aug 12. doi: 10.1016/j.actbio.2025.08.021.
9
High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration.
PeerJ. 2025 Jun 30;13:e19550. doi: 10.7717/peerj.19550. eCollection 2025.
10
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03195-7.
本文引用的文献
1
Comprehensive analysis reveals PLK3 as a promising immune target and prognostic indicator in glioma.
Oncol Res. 2025 Jan 16;33(2):431-442. doi: 10.32604/or.2024.050794. eCollection 2025.
2
Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer.
Cell Rep. 2023 Dec 26;42(12):113266. doi: 10.1016/j.celrep.2023.113266. Epub 2023 Nov 17.
3
Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1.
J Exp Clin Cancer Res. 2023 Nov 16;42(1):302. doi: 10.1186/s13046-023-02872-1.
4
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Blood. 2023 Dec 7;142(23):2002-2015. doi: 10.1182/blood.2023019782.
5
Advancements in Cancer Immunotherapies.
Vaccines (Basel). 2022 Dec 27;11(1):59. doi: 10.3390/vaccines11010059.
6
Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis.
Nat Commun. 2023 Jan 17;14(1):251. doi: 10.1038/s41467-022-35348-5.
7
Multiple centrosomes enhance migration and immune cell effector functions of mature dendritic cells.
J Cell Biol. 2022 Dec 5;221(12). doi: 10.1083/jcb.202107134. Epub 2022 Oct 10.
8
PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC.
Comput Math Methods Med. 2022 Sep 20;2022:6302234. doi: 10.1155/2022/6302234. eCollection 2022.
9
Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.
Cancer Res. 2022 Oct 4;82(19):3532-3548. doi: 10.1158/0008-5472.CAN-22-0018.
10
PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC.
Int J Med Sci. 2021 Aug 19;18(15):3516-3525. doi: 10.7150/ijms.60135. eCollection 2021.
Zotero 插件